Core Viewpoint - Roche has launched the cobas® MPX-E assay, a qualitative in-vitro test for the simultaneous detection of HIV, Hepatitis C, B, and E viruses, enhancing donor screening and laboratory efficiency [1][2][8] Group 1: Product Features and Benefits - The cobas MPX-E assay consolidates the detection of four major viral targets into a single workflow, improving laboratory operations and patient safety [1][8] - The assay features dual-target detection for HIV-1 group M, enhancing sensitivity and reliability even with viral mutations [3] - It allows for flexible testing options, enabling laboratories to test for all four targets or select specific ones based on their needs [5][8] - The assay runs on the fully automated cobas x800 systems, which are capable of conducting over 10 million tests per month [4][8] Group 2: Market Context and Impact - Nucleic Acid Testing (NAT) blood screening is valued at approximately 800 million CHF globally, with a projected Compound Annual Growth Rate of +2% from 2024 to 2029 [3] - Hepatitis E (HEV) accounts for an estimated 20 million infections and 70,000 deaths annually, highlighting the importance of robust screening to manage blood supply risks [2] - The cobas MPX-E assay provides faster turnaround times and a cost-effective solution for laboratories implementing HEV screening without needing additional space or instrumentation [6][8]

Core Viewpoint - Roche has launched the cobas® MPX-E assay, a qualitative in-vitro test for the simultaneous detection of HIV and Hepatitis viruses, enhancing donor screening and laboratory efficiency [1][2]. Group 1: Product Features and Benefits - The cobas MPX-E assay consolidates the detection of four major viral targets (HIV, HCV, HBV, HEV) into a single workflow, improving safety for blood products [1][8]. - The assay features dual-target detection for HIV-1 group M, enhancing sensitivity and reliability even with viral mutations [3]. - It is designed for use on the fully automated cobas x800 systems, allowing for high-throughput testing and up to eight hours of walk-away time [4][8]. Group 2: Market Context and Impact - Nucleic Acid Testing (NAT) blood screening is valued at approximately 800 million CHF globally, with a projected Compound Annual Growth Rate of +2% from 2024 to 2029 [3]. - Hepatitis E (HEV) accounts for an estimated 20 million infections and 70,000 deaths annually, highlighting the importance of robust screening to manage blood supply risks [2]. Group 3: Company Overview - Roche is a leading healthcare company founded in 1896, focusing on diagnostics and pharmaceuticals across various disease areas, including infectious diseases [6]. - The company operates in over 150 countries, aiming to address significant healthcare challenges and improve patient outcomes [6].